Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations
James C. King(Biomedical Advanced Research and Development Authority), Rick A. Bright(Waterford Institute), Richard E. Rothman(Rush University Medical Center), Melissa Swope Willis(Biomedical Advanced Research and Development Authority), Robert Walker(University of Edinburgh), Timothy M. Uyeki(Cambodia National Malaria Center), David M. Vock(Clinical Research Institute), Andrea Dugas(Johns Hopkins University), Michael G. Ison(MDA Engineering (United States)), LaRee A Tracy(United States Food and Drug Administration), Peter Miele(United States Food and Drug Administration), James Zhou(Biomedical Advanced Research and Development Authority), Kimberly L. Armstrong(Biomedical Advanced Research and Development Authority), John Tegeris(Biomedical Advanced Research and Development Authority), James D. Neaton(University of Minnesota), Wendy Carter(United States Food and Drug Administration)
Cited by 16
Related Papers
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
|The Lancet|2000|2k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k
Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
|New England Journal of Medicine|2010|1.1k
Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection
|The Journal of Infectious Diseases|2010|864